US Eye, LLC

Located in Sarasota, Florida, US Eye, LLC specializes in advanced eye care services, including multi-specialty ophthalmology and innovative surgical procedures, enhancing patient experiences and vision quality through skilled practitioners and cutting-edge technology. US Eye, LLC, founded in 2019, operates in the field of eye care, focusing on delivering a wide range of ophthalmologic services. The firm is led by CEO Brad Logan. US Eye has engaged in a single investment deal, with the most recent transaction occurring on July 16, 2019, when Pamlico Capital invested in the company without disclosing the financial terms.

US Eye offers a comprehensive suite of eye care services, focusing on delivering high-quality patient care through advanced medical technologies and skilled practitioners. The core offerings include multi-specialty ophthalmology services, optometry, and innovative surgical procedures such as the iDoseTR implant for glaucoma management. Founded with the mission of enhancing patient experiences, US Eye leverages state-of-the-art technology and uniquely trained physicians to address various eye conditions, ultimately improving patients' vision quality and overall life satisfaction. Its clientele includes patients seeking routine eye examinations, surgical interventions, and specialized care across geographical markets, including Florida and North Carolina.

US Eye generates revenue primarily through direct patient services, which include consultations, diagnostic testing, and surgical procedures. The business model is structured around direct-to-consumer transactions, where patients access services on a fee-for-service basis. Partnerships with local eye care practices allow for a collaborative approach, enhancing service offerings and maximizing patient satisfaction. Revenue is bolstered through specialty treatments and advanced technologies such as the iDoseTR implant, which represent key service lines within their portfolio.

The company’s financial structure is supported by patient insurance reimbursements and out-of-pocket payments for elective procedures, ensuring a steady revenue stream while maintaining a focus on delivering exceptional care outcomes. US Eye, LLC plans to utilize the funding received from Pamlico Capital in July 2019 to promote its growth. This includes the development and launch of new products designed to enhance patient care and treatment outcomes. Additionally, the company is targeting expansion into new markets, specifically aiming to establish a presence in underserved regions where premium eye care services are needed.

The specifics of these geographic expansions and new product launches are not detailed at this time.